Market Sentiment for REGN

Sentiment and Price Analysis

Live Market Insights

Live Market Sentiment

Neutral (0.0966)

(Latest daily score)

Predicted Return

32.73%

7-day sentiment average

Advisory Opinion

Buy

Derived from sentiment trend

News Items (period)

1,820

Recent Headlines for REGN

The table below gives each of the most recent headlines of the stock and the negative, neutral, positive aggregated sentiment score.

Date	Headline	Source	Sentiment
2026-04-04	Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists	Simply Wall St.	Negative (-0.1443)
2026-04-03	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?	Zacks	Strong Positive (0.6603)
2026-04-03	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar	Zacks	Positive (0.1999)
2026-04-03	Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know	StockStory	Strong Negative (-0.5704)
2026-04-02	Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions	GlobeNewswire	Positive (0.2988)
2026-04-02	TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions	PR Newswire	Positive (0.3109)
2026-04-02	Trump Administration Unveils Up to 100% Tariff on Branded Drugs	The Wall Street Journal	Positive (0.2523)
2026-04-02	Trump Slaps 100% Tariffs on Some Drug Imports. What to Know.	Barrons.com	Negative (-0.1610)
2026-04-02	Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy	Zacks	Strong Positive (0.8241)
2026-04-02	EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)	GlobeNewswire	Strong Positive (0.8167)